Reviewing MDxHealth (NASDAQ:MDXH) & Guardant Health (NASDAQ:GH)

MDxHealth (NASDAQ:MDXH – Get Rating) and Guardant Health (NASDAQ:GH – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Profitability

This table compares MDxHealth and Guardant Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	N/A	N/A	N/A
Guardant Health	-140.58%	-145.58%	-30.70%

Institutional and Insider Ownership

12.6% of MDxHealth shares are owned by institutional investors. Comparatively, 90.4% of Guardant Health shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 5.9% of Guardant Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares MDxHealth and Guardant Health’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$22.24 million	5.12	-$29.00 million	N/A	N/A
Guardant Health	$373.65 million	8.34	-$405.67 million	($5.93)	-5.13

MDxHealth has higher earnings, but lower revenue than Guardant Health.

Volatility and Risk

MDxHealth has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, Guardant Health has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for MDxHealth and Guardant Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	0	0	2	0	3.00
Guardant Health	0	1	15	0	2.94

MDxHealth currently has a consensus target price of $16.50, suggesting a potential upside of 136.05%. Guardant Health has a consensus target price of $90.39, suggesting a potential upside of 197.04%. Given Guardant Health’s higher probable upside, analysts plainly believe Guardant Health is more favorable than MDxHealth.

Summary

Guardant Health beats MDxHealth on 7 of the 12 factors compared between the two stocks.

About MDxHealth

(Get Rating)

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About Guardant Health

(Get Rating)

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.